This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Wednesday's Health Winners & Losers

Health stocks fell Wednesday, hit by the continuing effects of a bum trial, and a handful of disappointing earnings.

The bright spot was Encysive (ENCY), whose shares more than doubled after Pfizer (PFE - Get Report) agreed to buy the troubled company for $2.35 a share, or about $195 million. The deal represents a more than 100% premium to Encysive's closing share price Tuesday of $1.08. Shares added $1.20 to $2.27.

Shares of Pfizer, which will gain rights to Encysive's pipeline and pulmonary arterial hypertension drug Thelin, lost 10 cents to $22.47.

On the down side, Onyx (ONXX) lost ground for the second straight day following news that the biotech and partner Bayer AG ended a late-stage trial on their drug Nexavar in lung cancer patients. The stock, which lost more than 20% on Tuesday, sank another $2.35, or 6.9%, to $30.80, on Wednesday.

Onyx contributed to a drop in the Nasdaq biotechnology index, which fell 0.7% to 788.08.

Elsewhere, Inverness Medical Innovations (IMA) plunged 16% even after the company reported better-than-expected fourth-quarter results. Inverness posted a loss of 19 cents a share, compared to a profit of 15 cents a share a year earlier.

But on an adjusted basis, the company said its earnings per share rose to 40 cents from 34 cents a year earlier. Analysts surveyed by Thomson Financial were looking for 38 cents a share, on average.

Inverness shares fell $7.04 to $36.83. Matria Healthcare (MATR - Get Report) -- which agreed last month to be acquired by Inverness for $900 million -- shed $1.94, or 6.6%, to $27.45.

Medical-device company Xtent (XTNT) also declined on its fourth-quarter report. The company posted a loss of $11.9 million, or 52 cents a share, based on 22.8 million weighted average shares outstanding. In the year-ago quarter the company had a loss of $7.2 million, or $2.46 a share, based on 2.9 million weighted average shares outstanding. Its stock gave up $1.40 to $8.11.

Kindred Healthcare (KND - Get Report) shares tumbled on a disappointing first-quarter forecast. The health care services company said after the bell Tuesday that its fourth-quarter profit fell to $16.3 million, or 43 cents a share, from $22.1 million, or 56 cents a share, in the year-earlier period.

Excluding items, Kindred Healthcare did surpass the Thomson Financial average analyst target by two cents, earning 51 cents a share. For the first quarter, however, the company forecast earnings of 22 cents to 27 cents a share, well below analysts' target of 39 cents. Shares declined $2.58, or 10%, to $23.25.

One stock higher on earnings was Cyberonics (CYBX - Get Report), which soared 17% after the device maker posted a narrower-than-expected quarterly loss and announcing plans to buy back up to 1 million shares. The company reported a loss of $1 million, or 4 cents a share, narrowed from a loss of $19.4 million, or 76 cents a share, a year earlier.

Analysts polled by Thomson Financial were expecting a loss of 9 cents a share. The company's sales declined, but a 12% cut in staff helped to push down operating expenses. Shares of Cyberonics rose $1.68 to $11.41.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CYBX $64.87 0.00%
KND $24.33 0.00%
MATR $6.35 0.00%
PFE $34.53 0.00%
AAPL $123.25 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs